The Bristol-Myers Squibb (NYSE:BMY)-Pfizer (NYSE:PFE) Alliance said today that it is working with Fitbit (NYSE:FIT) to improve earlier detection of atrial fibrillation in individuals with an increased risk of stroke. Fitbit and the alliance plan to work together on the development of educational content and guidance in support of people at increased risk for Afib. Fitbit is seeking […]
Taris Bio, Bristol-Myers Squibb launch bladder cancer trial
Taris Biomedical has announced the dosing of the first patient in a study of its TAR-200 system plus a programmed immune checkpoint inhibitor for the treatment of muscle-invasive bladder cancer (MIBC). The TAR-200 system continuously delivers the chemotherapy drug gemcitabine in the bladder for multiple weeks. The combination with Bristol-Myers Squibb’s Opdivo (nivolumab) will be assessed for […]
Report: Pharma companies kick off new year with price hikes
Major pharmaceutical firms started the new year by hiking the prices of hundreds of drugs, according to a new study published by Rx Savings Solutions. First reported in The Wall Street Journal, the study found that the average price increase taken by more than three dozen companies was roughly 6.3%. Get the full story at our […]
Sanuwave confirms acting CEO Richardson as company head | Personnel Moves – December 12, 2018
Sanuwave said late last month that it lifted acting CEO and board chair Kevin Richardson to a permanent position in the corner office. Richardson joined the Suwanee, Ga.-based company in 2009 as board chair, and has served as acting CEO since 2014. He also served as managing partner of investment management firm Prides Capital from […]
Motus GI taps Moran as CEO | Personnel Moves – September 25, 2018
Motus GI said today that it named Timothy Moran as its new chief executive officer, effective October 1, replacing former CEO Mark Pomeranz who will assume the role of president and COO. Moran has previously served ConvaTec‘s (LON:CTEC) Americas president and helped lead the company through its initial public offering in 2016. Prior to ConvaTec, Moran spent […]
New Abingworth fund beats expectations
Lifesciences investment group Abingworth Bioventures has closed its latest fund, Abingworth Bioventures VII (ABV VII) at $315 million. The fund — Abingworth’s 12th invested in companies in Europe and the U.S. — exceeded its target of $300 million. The firm has more than $1.2 billion under management. The fund invests broadly across all stages of development, […]
Bristol-Myers Squibb, Illumina to develop companion diagnostics for immunotherapies
Bristol-Myers Squibb (NYSE:BMY) is joining forces with Illumina (NSDQ:ILMN) to develop and commercialize diagnostic tests to support Bristol’s portfolio of cancer drugs. The companies announced last week that they plan to develop an assay to measure predictive genomic biomarkers, like tumor mutation burden, that could help doctors identify patients that will benefit from Bristol’s immunotherapies. Get the full […]
EU committee backs dosing changes for Bristol-Myers Squibb’s immunotherapy
A committee for the European Union’s pharmaceutical regulatory agency backed changes to the dosing schedule for Bristol-Myers Squibb‘s (NYSE:BMY) Opdivo cancer drug, the company touted today. The Committee for Medicinal Products for Human Use recommended that the European Commission approve a dosing schedule of 480-mg infused over 60 minutes every four weeks as an option for […]
Nektar lands record $3.6B deal with Bristol-Myers Squibb for cancer immunotherapy
Bristol-Myers Squibb (NYSE:BMY) could fork over as much as $3.63 billion for the rights to Nektar Therapeutics‘ (NSDQ:NKTR) cancer immunotherapy drug, according to a deal announced today by the two companies. Nektar’s NKTR-214, which is still in development, is designed to boost the number of cancer-killing T-cells around the tumor’s micro-environment. Bristol-Myers Squibb plans to pair the […]
Neovasc taps former Boston Scientific CRM vet Colen for CEO | Personnel Moves January 22, 2018
Neovasc (NSDQ:NVCN) said today it tapped former Boston Scientific (NYSE:BSX) cardiac rhythm management lead Fred Colen as its new chief executive officer, with former CEO Alexei Marko staying on as an advisor and member of the company’s board of directors. The move comes as part of a company-wide strategy looking to support commercialization efforts for its Reducer […]
Taris Biomedical lands $25m Series B following Bristol-Myers deal
One day after announcing a research collab with Bristol-Myers Squibb (NYSE:BMY), Taris Biomedical revealed that it has raised $25 million in a Series B round. Bristol-Myers also contributed to the round, which was led by Yonghua Capital. Get the full story at our sister site, Drug Delivery Business News.
MassDevice Network
@MassDevice
LinkedIn
YouTube